ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1169 • ACR Convergence 2022

    Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration

    Pablo Weilg Espejo1, Taha Dinc2, Fatima El Adili3, Maria Trojanowska4 and Andreea Bujor4, 1Boston Medical Center, Chelsea, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine, Revere, MA, 4Boston University, Boston, MA

    Background/Purpose: The mononuclear phagocytic system in Systemic Sclerosis (SSc) is central to fibrogenesis and may contribute to fibrosis via enhanced monocyte migration into injured tissues…
  • Abstract Number: 1168 • ACR Convergence 2022

    Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis

    Heetaek Yang1, Rajan Bhandari1, Noelle Kosarek2, Jonathan Garlick3, Michael Whitfield4 and Patricia Pioli1, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Dartmouth Geisel School of Medicine, Lebanon, NH, 3Tufts University School of Dental Medicine, Boston, MA, 4Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Macrophage (MØ) activation derives from coordination of signals received in local tissue microenvironments. In prior studies, we demonstrated that cocultured MØs and fibroblasts from…
  • Abstract Number: 1167 • ACR Convergence 2022

    Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages

    Sasha Shenk1, Jonathan Garlick1, Lev Brown2, Jamie Riesenberg2, Christian Evans2, Julia Jaffe Zweifach2, Andrew Macklin2, Tamar Abel3, Noelle Kosarek4, Mengqi Huang5, Avi Smith1, Tammara Wood3, Gretel Torres6, Patricia pioli6 and Michael Whitfield7, 1Tufts University School of Dental Medicine, Boston, MA, 2Tufts University, Boston, MA, 3Dartmouth College, Hanover, NH, 4Dartmouth Geisel School of Medicine, Lebanon, NH, 5University of Pittsburgh, Pittsburgh, PN, 6Geisel School of Medicine at Dartmouth, Lebanon, NH, 7Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH

    Background/Purpose: Scleroderma (Systemic Sclerosis; SSc) is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction, fibrosis, and inflammation. A lack of human…
  • Abstract Number: 1161 • ACR Convergence 2022

    IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

    Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

    Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
  • Abstract Number: 1173 • ACR Convergence 2022

    Single-cell Multi-omic Analysis of a 3D Skin-Like Tissue Model Provides Insights into Molecular and Cellular Drivers of Systemic Sclerosis

    Tamar Abel1, Noelle Kosarek2, Rezvan Parvizi3, Helen Jarnagin1, Mengqi Huang4, Avi Smith5, Michael Mariani1, Dillon Popovich6, Heetaek Yang7, Tammara Wood8, Jonathan Garlick9, Patricia Pioli7 and Michael Whitfield10, 1Dartmouth College, Lebanon, NH, 2Dartmouth Geisel School of Medicine, Lebanon, NH, 3Dartmouth, Lebanon, NH, 4University of Pittsburgh, Pittsburgh, PN, 5Tufts University, Boston, MA, 6Dartmouth College, West Lebanon, NH, 7Geisel School of Medicine at Dartmouth, Lebanon, NH, 8Dartmouth College, Hanover, NH, 9Tufts University School of Dental Medicine, Boston, MA, 10Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Systemic Sclerosis (SSc) currently lacks reliable in vitro models of skin fibrosis constructed from all human cells. We have developed a skin-like tissue model of systemic…
  • Abstract Number: 1174 • ACR Convergence 2022

    Cellular Immunotherapy for Systemic Sclerosis

    Chanhyuk Park1, Rajan Bhandari2, Jason Gunn3, Timothy Sullivan2, Gretel Torres2, Joana Murad3, Michael Whitfield4 and Patricia Pioli2, 1Geisel School of Medicine at Dartmouth, West Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Celdara Medical, Lebanon, 4Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Pro-fibrotic macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc). In prior work, we and others have shown that MØs derived from…
  • Abstract Number: 1164 • ACR Convergence 2022

    Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience

    Judith Rademacher1, Katharina Deschler2, Sonja Lacher2, Alina Huth2, Markus Utzt2, Stefan Krebs2, Helmut Blum2, Eduardo Beltrán2, Klaus Dornmair2 and Denis Poddubnyy3, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU Munich, Munich, Germany, 3Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Spondyloarthritis (SpA) is strongly associated with HLA-B27. The arthritogenic antigen hypothesis assumes the existence of specific peptides presented by risk-conferring HLA-B27 alleles to antigen-specific…
  • Abstract Number: 1172 • ACR Convergence 2022

    Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts

    Juan-Pablo Zertuche1, Taha Dinc2, Fatima El Adili3, Giovanni Ligresti1 and Andreea Bujor1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine, Revere, MA

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by immune system activation, endothelial dysfunction and widespread tissue fibrosis. Activation of the monocyte/macrophage…
  • Abstract Number: 1185 • ACR Convergence 2022

    Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis

    Wenjing Ye1, Qian Wang1, Li Zhao2, Changcheng Wang3, Dandan Zhang4, Mengyu Zhou4, Fangfang Chen2, Zaihua Zhu2, Weiguo Wang2, Wenyu Guo5, Yun Liu4, Hejian Zou2 and Yu Xue2, 1epartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, 2Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, 3Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, 4MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China, 5Clinical Development, I-Mab Biopharma (Hangzhou) Co., Ltd, Shanghai, China

    Background/Purpose: Interleukin-11 (IL-11) was found significantly upregulated in Systemic sclerosis (SSc), the aim of this study is to explore the pathological role of IL-11 and…
  • Abstract Number: 1179 • ACR Convergence 2022

    Single Cell RNA Sequencing Analysis of Cryopreserved versus Fresh Skin Biopsy Samples from Systemic Sclerosis Patients and Healthy Controls

    Brian Skaug1, Marka Lyons1, Julio Charles1, Maureen Mayes2 and Shervin Assassi3, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 3McGovern Medical School, University of Texas, Houston, TX

    Background/Purpose: Single cell RNA Sequencing (scRNA-Seq) can elucidate tissue-resident cell populations and gene expression profiles with unprecedented granularity. Application of this approach to systemic sclerosis…
  • Abstract Number: 1181 • ACR Convergence 2022

    Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis

    Feiyang Ma1, Pei-Suen Tsou1, Grace Hile1, John Varga1, J. Michelle Kahlenberg1, Allison Billi1, Johann Gudjonsson1 and Dinesh Khanna2, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is a devastating autoimmune disease characterized by excessive production and accumulation of extracellular matrix molecules leading to fibrosis of skin and…
  • Abstract Number: 1177 • ACR Convergence 2022

    Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis

    Amela Hukara1, Tracy Tabib2, Michal Rudnik1, Oliver Distler3, Przemyslaw Blyszczuk1, Robert Lafyatis2 and Gabriela Kania1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Phagocytosis is a crucial cellular process, which under certain immuno-pathological conditions can be activated in macrophages in an uncontrolled manner. Biomarker studies have implicated…
  • Abstract Number: 1188 • ACR Convergence 2022

    Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

    Kate Orroth1, Cristi Cavanaugh2, Xi Qian2, Pam Kumparatana2, Yuri Klyachkin3, Stephen Colgan4 and Myriam Cordey4, 1Amgen, Manhattan Beach, CA, 2OM1, Inc., Boston, MA, 3Amgen, Lexington, KY, 4Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Patients with PsO and PsA have a higher prevalence of cardiometabolic comorbidities like diabetes compared to the general population. Clinical data have shown apremilast…
  • Abstract Number: 1187 • ACR Convergence 2022

    Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

    Kate Orroth1, Cristi Cavanaugh2, Xi Qian2, Pam Kumparatana2, Yuri Klyachkin3, Stephen Colgan4 and Myriam Cordey4, 1Amgen, Manhattan Beach, CA, 2OM1, Inc., Boston, MA, 3Amgen, Lexington, KY, 4Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Obesity prevalence is higher in patients with PsO and PsA than the general population. Weight loss may improve PsO disease severity in obese patients.…
  • Abstract Number: 1130 • ACR Convergence 2022

    Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics

    Carlos Pérez-Sánchez1, Laura Muñoz-Barrera1, Tomás Cerdó2, Ismael Sánchez-Pareja2, Jerusalem Calvo-Gutierrez2, Rafaela Ortega-Castro1, Montserrat Romero-Gomez2, María Ángeles Aguirre-Zamorano3, María Carmen Ábalos-Aguilera4, Nuria Barbarroja1, José Perez-Venegas5, Mª Dolores Ruiz-Montesinos5, Carmen Dominguez5, Carlos Rodriguez-Escalera6, Carmen Romero-Barco6, Antonio Fernandez-Nebro7, Natalia Mena Vazquez7, Jose Luis Marenco8, Julia Uceda Montañez8, Charo Santos9, Eduardo Collantes1, Alejandro Escudero-Contreras2 and Chary Lopez-Pedrera1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 4Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 5Virgen Macarena University Hospital, Sevilla, Spain, 6Virgen de la Victoria Hospital, Málaga, Spain, 7Regional University Hospital of Málaga, Málaga, Spain, 8Virgen de Valme University Hospital, Sevilla, Spain, 9Virgen de Valme University Hospital, Málaga, Spain

    Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
  • « Previous Page
  • 1
  • …
  • 559
  • 560
  • 561
  • 562
  • 563
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology